Literature review on treatment of immune thrombocytopenia secondary to refractory systemic lupus erythematosus with belimumab combined with cyclosporine: A case report and literature review

doi:10.3969/j.issn.1004-583X.2022.06.012

Abstract

Abstract:

Objective To explore the effects of belimumab on systemic lupus erythematosus (SLE) complicated with refractory hematological damage. Methods A SLE patient mainly featured with refractory hematological damage admitted to Guizhou Provincial People's Hospital was retrospectively analyzed. Results The female patient with more than 1 year history of SLE was admitted to hospital for sub dermal ecchymosis complicated with abdominal pain lasting 10 days, was clearly diagnosed as SLE with refractory blood system damage after hospitalization. The patient's condition was significantly improved without adverse reactions after maintenance therapy with belimumab in addition to basic treatment including cyclosporine. The patient was followed up for more than 1 year, the glucocorticoid dosage was minimized, and no recurrence of disease was found. Conclusion Combination of belimumab with cyclosporine in the treatment of refractory SLE secondary immune thrombocytopenia provides a new treatment option, and more clinical efficacy remains to be observed and evaluated in the long term.

Key words: lupus erythematosus,systemic, purpura,thrombocytopenia,idiopathic, antibodies,monoclonal

CLC Number:

R593.241

Qin Meijie, Tian Maolu, Yang Yuqi, Zha Yan, Yuan Jing. Literature review on treatment of immune thrombocytopenia secondary to refractory systemic lupus erythematosus with belimumab combined with cyclosporine: A case report and literature review[J]. Clinical Focus, 2022, 37(6): 544-547.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.06.012

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I6/544

Figures/Tables 2

References 17

[1]	Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus[J]. Lupus Sci Med, 2015, 2(1):e000078. doi: 10.1136/lupus-2014-000078 URL
[2]	Audia S, Mahevas M, Samson M, et al. Pathogenesisi of im-mune thrombocytopenia[J]. Autoimmun Rev, 2017, 16(6):620-632. doi: 10.1016/j.autrev.2017.04.012 URL
[3]	Baroni Pietto MC, Lev PR, Glembotsky AC, et al. Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus[J]. Platelets, 2021, 21:1-12. doi: 10.3109/09537100903391015 URL
[4]	龙现明, 蔡成森. 系统性红斑狼疮继发难治性血小板减少的临床特征分析[J]. 中华风湿病学杂志, 2020, 24(3):203-205.
[5]	中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3):172-185.
[6]	Ilizaliturri-Guerra O, Uriarte-Botello R, Pineda-Sic RÁ, et al. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus[J]. Rheumatol Int, 2020, 40(10):1717-1724. doi: 10.1007/s00296-020-04668-4 pmid: 32797277
[7]	Yudhishdran J, Sivakumar J, Navinan MR, et al. Rituximab induced acute thrombocytopenia in a patient with systemic lupus erythematosus: A case report[J]. J Med Case Rep, 2021, 15(1):339. doi: 10.1186/s13256-021-02950-y URL
[8]	Kumar S, Benseler SM, Kirby-Allen M, et al. B-cell deple-tion for autoimmune thrombocytopenia and autoimmune hemolyticanemia in pediatric systemic lupus erythematosus[J]. Pediatrics, 2009, 123(1):159-163.
[9]	Samy E, Wax S, Huard B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases[J]. Int Rev Immunol, 2017, 36(1):3-19. doi: 10.1080/08830185.2016.1276903 URL
[10]	Depascale R, Gatto M, Zen M, et al. Belimumab: A step forward in the treatment of systemic lupus erythematosus[J]. Expert Opin Biol Ther, 2021, 21(5):563-573. doi: 10.1080/14712598.2021.1895744 URL
[11]	Teng YKO, Bruce IN, Diamond B, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol[J]. BMJ Open, 2019, 9(3):e025687. doi: 10.1136/bmjopen-2018-025687 URL
[12]	Xu P, Shao X, Ou Y, et al. Neutrophils contribute to elevated BAFF levels to modulate adaptive immunity in patients with primary immune thrombocytopenia by CD62P and PSGL1 interaction[J]. Clin Transl Immunol, 2022, 11: e1399.
[13]	Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis[J]. Kidney Int, 2022, 101(2):403-413. doi: 10.1016/j.kint.2021.08.027 URL
[14]	Urowitz MB, Ohsfeldt RL, Wielage RC, et al. Organ damage in patients treated with belimumab versus standard of care: A propensity score-matched comparative analysis[J]. Ann Rheum Dis, 2019, 78: 372-379. doi: 10.1136/annrheumdis-2018-214043 pmid: 30610066
[15]	Sheikh SZ, Scheinberg MA, Cheng-Chung Wei, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): A multicentre, double-blind, randomised, placebo-controlled, phase 4 trial[J]. Lancet Rheumatol, 2021, 3: e122-e 130.
[16]	Kraaij T, Arends EJ, van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results[J]. Nephrol Dial Transplan, 2021, 36(8):1474-1483. doi: 10.1093/ndt/gfaa117 URL
[17]	冯秀媛, 闫慧明, 王永福, 等. 系统性红斑狼疮血液系统受累的相关性分析[J]. 临床荟萃, 2011, 26(23): 2086-2088.